These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30207910)

  • 1. Limiting State Flexibility in Drug Pricing.
    Bagley N; Sachs RE
    N Engl J Med; 2018 Sep; 379(11):1002-1004. PubMed ID: 30207910
    [No Abstract]   [Full Text] [Related]  

  • 2. Will Courts Allow States to Regulate Drug Prices?
    Robertson C
    N Engl J Med; 2018 Sep; 379(11):1000-1002. PubMed ID: 30088965
    [No Abstract]   [Full Text] [Related]  

  • 3. Legal Challenges to State Drug Pricing Laws.
    Lee TT; Kesselheim AS; Kapczynski A
    JAMA; 2018 Mar; 319(9):865-866. PubMed ID: 29435585
    [No Abstract]   [Full Text] [Related]  

  • 4. States on the Front Line: Addressing America's Drug Pricing Problem.
    Riley T; Lanford S
    J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
    [No Abstract]   [Full Text] [Related]  

  • 5. Lowering Part D drug costs without direct CMS negotiations.
    Sipkoff M
    Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicare and Medicaid programs; limits on payments for drugs--HCFA. Final rule.
    Fed Regist; 1987 Jul; 52(147):28648-58. PubMed ID: 10301766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. States as Activists.
    Buck ID
    J Leg Med; 2019; 39(2):121-136. PubMed ID: 31503528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
    Greene JA; Padula WV
    N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 10. The war on drug--prices: states are taking up the fight to reduce prescription drug costs.
    Boulard G
    State Legis; 2002 Mar; 28(3):12-7. PubMed ID: 11873811
    [No Abstract]   [Full Text] [Related]  

  • 11. HCFA orders states to cover Clozaril costs; watchdog group urges warning on drug.
    Wagner M
    Mod Healthc; 1991 Jun; 21(22):14. PubMed ID: 10110762
    [No Abstract]   [Full Text] [Related]  

  • 12. Access to pharmaceuticals under Medicaid managed care: federal law compiled and state contracts compared.
    Loza EL
    Food Drug Law J; 2000; 55(3):449-76. PubMed ID: 11824469
    [No Abstract]   [Full Text] [Related]  

  • 13. A prescription for a modern Medicare program.
    Bach PB; McClellan MB
    N Engl J Med; 2005 Dec; 353(26):2733-5. PubMed ID: 16382056
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicare Coverage of Aducanumab - Implications for State Budgets.
    Sachs RE; Bagley N
    N Engl J Med; 2021 Nov; 385(22):2019-2021. PubMed ID: 34797617
    [No Abstract]   [Full Text] [Related]  

  • 15. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 16. Will State Waivers Save, Reform, or Sabotage Obamacare?
    Butler SM
    JAMA; 2019 Feb; 321(5):441-442. PubMed ID: 30721284
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252884
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
    [No Abstract]   [Full Text] [Related]  

  • 20. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.